<?xml version="1.0"?>
<notificationOfRemoval>

    <schemaVersion>X0203</schemaVersion>

    <exchange>
        <cik>0001354457</cik>
        <entityName>Nasdaq Stock Market LLC</entityName>
    </exchange>

    <issuer>
        <cik>0001328143</cik>
        <entityName>Adamas Pharmaceuticals Inc</entityName>
        <fileNumber>001-36399</fileNumber>
        <address>
            <street1>2200 Powell Street</street1>
            <street2>Suite 220</street2>
            <city>Emeryville</city>
            <stateOrCountryCode>CA</stateOrCountryCode>
            <stateOrCountry>CALIFORNIA</stateOrCountry>
            <zipCode>94608</zipCode>
        </address>
        <telephoneNumber>510-4503560</telephoneNumber>
    </issuer>

    <descriptionClassSecurity>Common Stock</descriptionClassSecurity>

    <ruleProvision>17 CFR 240.12d2-2(a)(3)</ruleProvision>

    <signatureData>
        <signatureName>O'Neil Blake</signatureName>
        <signatureTitle>Senior Specialist</signatureTitle>
        <signatureDate>2021-11-24</signatureDate>
    </signatureData>
</notificationOfRemoval>